staurosporine has been researched along with taurochenodeoxycholic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coleman, R; Elias, E; Milkiewicz, P; Roma, MG | 1 |
| Jung, IL; Kim, SY; Kwon, YW; Park, SG; Sung, JH | 1 |
2 other study(ies) available for staurosporine and taurochenodeoxycholic acid
| Article | Year |
|---|---|
Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Bucladesine; Calcium; Carbazoles; Chelating Agents; Cholagogues and Choleretics; Cholestasis; Cholic Acids; Cyclic AMP-Dependent Protein Kinases; Egtazic Acid; Enzyme Activation; Enzyme Inhibitors; Indoles; Liver; Male; Protein Kinase C; Pyrroles; Rats; Signal Transduction; Staurosporine; Taurochenodeoxycholic Acid; Taurolithocholic Acid | 2002 |
Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCĪ±-mediated MKP-1 induction.
Topics: Animals; Apoptosis; Biological Transport; Carotid Artery Injuries; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Dual Specificity Phosphatase 1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperplasia; Liver-Specific Organic Anion Transporter 1; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Protein Kinase C-alpha; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; RNA Interference; Staurosporine; Taurochenodeoxycholic Acid; Time Factors; Transfection; Tunica Intima; Up-Regulation | 2011 |